Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PDS Biotechnology Corp
Report date October 08, 2015 · Filed December 31, 2018 · Amendment
Section 16 reporting ended · disclosed 2018-12-31. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirect401(K) Plan | 32,061.25 |
Reported balance
Holding disclosure · report date 2015-10-08 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 32,061.25 F1: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2018 Filed Aug 15, 2018 07:45 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 59,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025359 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,833 Underlying: Common Stock · 59,833 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 16:17 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 119,667 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021568 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,667 Underlying: Common Stock · 119,667 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 08:31 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 90,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009820 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 18:53 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-18-000822 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-02 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 15:23 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (right To Purchase) · Derivative | 110,000 | $8.86 Strike: $8.86 | $974,600.00 |
DisclosureSEC source: 0001127602-17-011763 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-03-13 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 110,000 shares of Common Stock, will become exercisable on February 17, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.